I am particularly interested in the treatment of people with thoracic malignancies, particularly lung cancer. I enjoy the clinical aspect of managing and treating patients and I blend this with a clinical research interest. I am actively involved in initiating research projects, which includes writing protocols, gathering data, analyzing and presenting the results. The next generation of therapy for lung cancer involves an integration of molecularly targeted agents designed to interfere with the growth and proliferation of cancer cells specifically. These projects have many correlative elements with the basic sciences that I find exciting and promising.
- D.N. Ionescu; D. Traeba, C.B. Gilks, S. Leung, D. Renouf, J. Laskin, R. Wood-Baker, A.M. Gown. Non-small Cell Lung Carcinoma With Neuroendocrine Differentiation-An Entity of No Clinical or Prognostic Significance. Am J Surg Pathol. 2007 Jan;31(1):26-32.
- T. J. Pugh, G. Bebb, L. Barclay, M. Sutcliffe, J. Fee, C. Salski, R. O’Connor, C. Ho, N. Murray, B. Melosky, J.English, J. Vielkind, D. Horsman, J. J Laskin and M. A. Marra. “Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients”. BMC Cancer 2007, 7:128 (13 Jul 2007).
- B. Johal; J. Laskin: “A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy.” Expert Rev Anticancer Ther. 2006 Oct;6(10):1411-9. Review.